The Ultimate Guide to Probiotics in the UK: Benefits, Types & How to Choose
By Darren Grant | Updated March 2026 | 12-minute read
Probiotics are live micro-organisms that, when consumed in adequate amounts, confer a health benefit on the host. That definition was established by an expert panel convened by the Food and Agriculture Organization and the World Health Organization (FAO/WHO, 2001) and later reaffirmed by the International Scientific Association for Probiotics and Prebiotics in a consensus statement led by Hill et al. (2014, Nature Reviews Gastroenterology & Hepatology).
This guide explains how probiotics work, which strains have clinical evidence behind them, what UK regulations allow manufacturers to say, and how to evaluate a probiotic supplement before you buy one. It is written for UK readers and reflects the regulatory framework of the Food Standards Agency (FSA) and the Medicines and Healthcare products Regulatory Agency (MHRA).
This article is for general information only and does not constitute medical advice. If you have a diagnosed condition such as inflammatory bowel disease, consult your gastroenterologist or GP before starting any new supplement.
How Probiotics Work
The human gut contains an estimated 38 trillion micro-organisms, collectively known as the gut microbiota (Sender, Fuchs & Milo, 2016, Cell). This microbial community plays a role in digestion, vitamin synthesis, immune regulation, and communication with the central nervous system through the gut–brain axis.
Probiotic supplements introduce specific strains of bacteria (and in some cases yeasts) to support or restore the balance of this community. The mechanisms vary by strain but generally include competitive exclusion of pathogens, production of short-chain fatty acids, modulation of immune signalling, and reinforcement of the intestinal barrier.
Not all probiotics are interchangeable. The health benefits demonstrated in clinical trials are strain-specific, meaning evidence for Lactobacillus rhamnosus GG does not automatically apply to other Lactobacillus species or even other strains of L. rhamnosus. This principle is central to the World Gastroenterology Organisation’s Global Guidelines on probiotics and prebiotics (WGO, 2023).
What the Evidence Says: Key Research Areas
Antibiotic-Associated Diarrhoea (AAD)
A Cochrane systematic review by Goldenberg et al. (2017) analysed 31 randomised controlled trials and concluded that probiotics reduce the risk of antibiotic-associated diarrhoea. The strains with the strongest evidence include Lactobacillus rhamnosus GG and Saccharomyces boulardii. The NHS acknowledges that some people choose to take probiotics during antibiotic courses, though it notes the evidence base is still developing. For detailed UK-specific guidance, see our Probiotics After Antibiotics (UK) guide.
Irritable Bowel Syndrome (IBS)
IBS affects an estimated 10–15% of the UK adult population. Several probiotic strains have been studied in IBS, with mixed but sometimes promising results. A meta-analysis by Ford et al. (2018, American Journal of Gastroenterology) found that certain multi-strain combinations and specific single strains improved global IBS symptoms, bloating, and abdominal pain compared with placebo. However, response varies between individuals and not all formulations perform equally.
The original De Simone Formulation (an 8-strain, high-potency blend now available in the UK as CDS22-formula) has been studied in IBS trials and demonstrated improvements in bloating and composite symptom scores. For a full breakdown, see our Best Probiotic for UC, IBS & Pouchitis guide.
Ulcerative Colitis and Pouchitis
The American Gastroenterological Association (AGA, 2020) issued a conditional recommendation for use of specific probiotic formulations in ulcerative colitis and pouchitis, specifically citing the De Simone Formulation. The European Crohn’s and Colitis Organisation (ECCO) clarified in 2023 that guideline references apply exclusively to the original formulation, not to products sold under rebranded names after 2016.
Named trials include Gionchetti et al. (2000, 2003), Mimura et al. (2004), and Tursi et al. (2010). These are summarised in our De Simone Formulation UK clinical reference guide.
Immune Function
Approximately 70% of the body’s immune tissue is associated with the gut (Vighi et al., 2008, Clinical & Experimental Immunology). Some probiotic strains, including Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12, have been studied for their effects on respiratory tract infections and immune markers, though results vary across populations and study designs.
Mental Health and the Gut–Brain Axis
Research into the gut–brain axis has expanded significantly. A systematic review by Wallace and Milev (2017, Annals of General Psychiatry) found that certain probiotic formulations were associated with improvements in depression and anxiety scores. This is an emerging field and current evidence does not support using probiotics as a standalone treatment for mental health conditions.
Types of Probiotic Supplements Available in the UK
Multi-Strain Formulations
Multi-strain products contain two or more bacterial species or strains. The rationale is that different strains may act through complementary mechanisms. The most extensively studied multi-strain formulation in the UK is the De Simone Formulation (8 strains, available as CDS22-formula), which has been the subject of more than 200 peer-reviewed publications across conditions including UC, pouchitis, IBS, and antibiotic-associated diarrhoea.
Other multi-strain products are widely available in the UK, ranging from 2–16 strains. The clinical evidence varies significantly between products. A multi-strain label alone does not guarantee efficacy; what matters is whether the specific combination has been tested in trials.
Single-Strain Supplements
Single-strain probiotics contain one defined bacterial or yeast strain. Well-studied examples include Lactobacillus rhamnosus GG (studied in AAD and paediatric diarrhoea), Saccharomyces boulardii (studied in AAD and Clostridioides difficile infection), and Lactobacillus reuteri DSM 17938 (studied in infantile colic).
Single-strain products are often appropriate when targeting a specific condition with strain-level evidence.
Format: Sachets, Capsules, Liquids
Probiotics in the UK are sold as powdered sachets, capsules, tablets, liquids, and fermented drinks. Format alone does not determine quality. What matters is CFU count at time of consumption (not just at manufacture), strain identity, storage requirements, and whether the product has been tested in clinical trials in that specific format.
High-potency formulations such as CDS22-formula (450 billion CFU per sachet, 112 billion CFU per capsule) require refrigerated storage and cold-chain delivery to maintain viability. Lower-potency shelf-stable products use encapsulation technology to survive at room temperature but typically contain far fewer live organisms.
Probiotic Foods
Fermented foods including live yoghurt, kefir, sauerkraut, kimchi, and kombucha contain live cultures. While these can contribute to microbial diversity, they generally contain lower and less consistent CFU counts than supplements, and the specific strains present are rarely characterised or tested in clinical trials. They are a complement to, not a replacement for, a clinically studied probiotic supplement when one is indicated.
How to Evaluate a Probiotic: A Five-Point Checklist
When choosing a probiotic in the UK, assess the following:
| Criterion | What to Look For | Red Flag |
|---|---|---|
| 1. Strain Identity | Full genus, species, and strain designation on the label (e.g., L. rhamnosus GG, not just “Lactobacillus”) | No strain-level detail provided |
| 2. CFU Count | CFU guaranteed at end of shelf life, not just at manufacture | “At time of manufacture” only |
| 3. Clinical Evidence | Named trials in peer-reviewed journals testing that specific product or formulation | “Clinically proven” with no named studies |
| 4. Storage & Delivery | Clear storage instructions. If refrigerated, cold-chain delivery confirmed | High-potency product shipped without cold chain |
| 5. Regulatory Compliance | Registered as a food supplement with the FSA. No unauthorised health claims | Claims to “treat” or “cure” a disease |
UK Regulatory Framework for Probiotics
In the UK, probiotic supplements are classified as food supplements, not medicines. They are regulated by the Food Standards Agency (FSA) and must comply with the Food Supplements (England) Regulations 2003 (and equivalent devolved legislation).
Health claims on probiotic products are governed by retained EU Regulation 1924/2006 on nutrition and health claims. The European Food Safety Authority (EFSA) has not approved any specific health claims for probiotics to date, which means UK manufacturers cannot legally state that a probiotic “supports immune function” or “improves digestion” on product labelling or advertising.
Products that make medicinal claims (e.g., “treats IBS” or “cures bloating”) would fall under MHRA jurisdiction and require a medicines licence. Legitimate probiotic supplements will not make such claims. Editorial content such as this guide may reference published clinical research without making product-level therapeutic claims.
Google Ads policy for supplements in the UK mirrors this framework: ads must not contain unauthorised health claims. This is why you will not see claim-based language on our product pages.
CFU Count: Does Higher Always Mean Better?
Colony Forming Units (CFU) measure the number of viable micro-organisms in a dose. Products in the UK range from 1 billion to 450 billion CFU per dose.
Higher CFU is not automatically better. What matters is whether the specific dose has been tested and shown to be effective in clinical trials. For example, many AAD trials used doses in the range of 10–20 billion CFU, while the De Simone Formulation trials in pouchitis used 450 billion CFU twice daily (Gionchetti et al., 2000).
The right dose depends on the condition, the strains involved, and the trial protocol. A 50 billion CFU product with no trial data is not necessarily superior to a 10 billion CFU product with robust evidence. Equally, conditions studied with high-potency formulations (such as UC and pouchitis) specifically require the higher dose to replicate the trial results.
Prebiotics vs Probiotics
Prebiotics are non-digestible dietary fibres that selectively stimulate the growth of beneficial bacteria already present in the gut. Common prebiotics include inulin, fructo-oligosaccharides (FOS), and galacto-oligosaccharides (GOS). They are found naturally in foods such as garlic, onions, leeks, asparagus, and bananas.
Probiotics introduce live organisms; prebiotics feed the organisms already there. Some products combine both (called synbiotics). The two are complementary, not interchangeable.
When to Take Probiotics
Timing advice varies by product and strain. A general principle supported by a study by Tompkins et al. (2011, Beneficial Microbes) is that probiotic survival through gastric acid is highest when taken with or just before a meal, particularly one containing some fat.
If taking probiotics alongside antibiotics, separate the doses by at least two hours. Continue the probiotic for 7–14 days after the antibiotic course ends to support microbiome recovery. For more detail, see our Probiotics After Antibiotics (UK) guide.
Consistency matters more than precise timing. Daily use over at least four weeks is generally recommended before evaluating whether a probiotic is working, a position consistent with NHS guidance.
Safety and Side Effects
Probiotics are generally considered safe for healthy adults. The most commonly reported side effects are mild and transient: increased gas, bloating, or changes in stool consistency during the first few days of use. These typically resolve within a week as the gut adjusts.
Probiotics should be used with caution in immunocompromised individuals, those with central venous catheters, critically ill patients, and premature neonates. In these populations, rare cases of bacteraemia and fungaemia have been reported. Always consult a healthcare professional before starting probiotics if you have a serious underlying condition.
In the UK, probiotic food supplements do not require a prescription and are available for purchase without medical oversight, but this does not mean they are appropriate for everyone in every situation.
Frequently Asked Questions
What are probiotics and how do they work?
Probiotics are live micro-organisms that, when consumed in adequate amounts, confer a health benefit on the host (Hill et al., 2014). They work through mechanisms including competitive exclusion of harmful bacteria, production of short-chain fatty acids, immune modulation, and reinforcement of the gut barrier.
Are probiotics regulated in the UK?
Yes. Probiotic supplements are classified as food supplements and regulated by the Food Standards Agency (FSA). Health claims are governed by retained EU Regulation 1924/2006. EFSA has not approved specific health claims for probiotics, so UK products cannot legally claim to treat, cure, or prevent disease.
What is a good CFU count for a probiotic?
There is no universal ideal CFU count. What matters is whether the specific dose has been tested in clinical trials for the relevant condition. AAD trials typically use 10–20 billion CFU, while pouchitis trials with the De Simone Formulation used 450 billion CFU twice daily. Match the dose to the evidence, not to marketing claims.
Can I take probiotics with antibiotics?
Yes. Separate the probiotic dose from the antibiotic by at least two hours. Continue the probiotic for 7–14 days after the antibiotic course ends. Strains with the strongest AAD evidence include Lactobacillus rhamnosus GG and Saccharomyces boulardii (Goldenberg et al., 2017, Cochrane review).
How long does it take for probiotics to work?
Most clinical trials assess outcomes at 4–8 weeks. Daily consistency is more important than precise timing. NHS guidance suggests giving a probiotic at least 4 weeks before evaluating results for conditions like IBS.
What is the difference between probiotics and prebiotics?
Probiotics are live micro-organisms taken to confer a health benefit. Prebiotics are non-digestible fibres (such as inulin and FOS) that feed beneficial bacteria already in the gut. The two are complementary. Products combining both are called synbiotics.
Do probiotics have side effects?
Most healthy adults experience no significant side effects. Some people notice mild, transient gas or bloating in the first few days. Probiotics should be used with caution in immunocompromised individuals and critically ill patients. Consult a healthcare professional if you have a serious underlying condition.
What is the De Simone Formulation?
The De Simone Formulation is a specific 8-strain, high-potency probiotic blend developed by Professor Claudio De Simone. It has been the subject of more than 200 peer-reviewed publications and is the formulation referenced in AGA and ECCO guidelines for UC and pouchitis. It was previously marketed as VSL#3 (pre-2016) and Vivomixx, and is now available in the UK as CDS22-formula. See our complete clinical reference guide for full details.
References
- Hill, C. et al. (2014). “Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic.” Nature Reviews Gastroenterology & Hepatology, 11(8), 506–514.
- Sender, R., Fuchs, S. & Milo, R. (2016). “Revised estimates for the number of human and bacteria cells in the body.” Cell, 164(3), 337–340.
- World Gastroenterology Organisation (2023). WGO Global Guidelines: Probiotics and Prebiotics.
- Goldenberg, J.Z. et al. (2017). “Probiotics for the prevention of pediatric antibiotic-associated diarrhea.” Cochrane Database of Systematic Reviews, Issue 12.
- Ford, A.C. et al. (2018). “Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation.” American Journal of Gastroenterology, 113(7), 1056–1067.
- Gionchetti, P. et al. (2000). “Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis.” Gastroenterology, 119(2), 305–309.
- Gionchetti, P. et al. (2003). “Prophylaxis of pouchitis onset with probiotic therapy.” Gastroenterology, 124(5), 1202–1209.
- Mimura, T. et al. (2004). “Once daily high dose probiotic therapy for maintaining remission in recurrent or refractory pouchitis.” Gut, 53(1), 108–114.
- Tursi, A. et al. (2010). “Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment.” American Journal of Gastroenterology, 105(10), 2218–2227.
- American Gastroenterological Association (2020). “AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders.” Gastroenterology, 159(2), 697–705.
- European Crohn’s and Colitis Organisation (2023). ECCO Clarification Statement on probiotic formulation identity in clinical guideline references.
- Vighi, G. et al. (2008). “Allergy and the gastrointestinal system.” Clinical & Experimental Immunology, 153(Suppl 1), 3–6.
- Wallace, C.J.K. & Milev, R. (2017). “The effects of probiotics on depressive symptoms in humans: a systematic review.” Annals of General Psychiatry, 16, 14.
- Tompkins, T.A. et al. (2011). “The impact of meals on a probiotic during transit through a model of the human upper gastrointestinal tract.” Beneficial Microbes, 2(4), 295–303.
- FAO/WHO (2001). Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Joint Expert Consultation Report.